Methoxyamine Hydrochloride is a small molecule commercialized by TRACON Pharmaceuticals, with a leading Phase II program in Lymphoma. According to Globaldata, it is involved in 9 clinical trials, of which 4 were completed, 3 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Methoxyamine Hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Methoxyamine Hydrochloride is expected to reach an annual total of $49 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Methoxyamine Hydrochloride Overview
TRC-102 (methoxyamine hydrochloride) is under development for the treatment of advanced or metastatic solid tumors, lung cancer, glioblastoma multiforme (GBM), lymphoma, ovarian cancer, colorectal cancer, mesothelioma. It is administered through oral and intravenous route. It is an inhibitor of base-excision repair intended to reverse resistance to alkylator and antimetabolite chemotherapy. It was under development for the treatment of relapsed or refractory hematologic malignancies, multiple myeloma,chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia, Hodgkin Lymphoma, diffuse large B-Cell lymphoma, nodal T-Cell Lymphomas, mantle cell lymphoma, anaplastic large cell lymphoma and follicular lymphoma
TRACON Pharmaceuticals Overview
TRACON Pharmaceuticals (TRACON) is a biopharmaceutical company. It develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TJ004309, TRC253, TRC694, and TRC205. Its lead product TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC102 is a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In addition, it also offers products for the treatment of fibrosis, prostate cancer, and hematologic malignancies such as myeloma. The company works in collaboration with universities and medical institutions. TRACON is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$28.4 million in FY2021, compared to an operating loss of US$16.2 million in FY2020. The net loss of the company was US$28.7 million in FY2021, compared to a net loss of US$16.8 million in FY2020.
For a complete picture of Methoxyamine Hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.